As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Darolutamide for non-metastatic castration-resistant prostate cancer.
This review discusses novel second-generation anti-androgens, pharmacological properties, mechanism of action and major studies featuring Darolutamide. It also provides commentary and recommendations from Dr. Laurence Krieger, a Consultant General Physician and undergraduate trainee supervisor for the Royal College of Physicians at Royal North Shore Hospital, Sydney.
Please login below to download this issue (PDF)